CN1251699C - Antiviral medicine composition and application thereof - Google Patents
Antiviral medicine composition and application thereof Download PDFInfo
- Publication number
- CN1251699C CN1251699C CNB03126705XA CN03126705A CN1251699C CN 1251699 C CN1251699 C CN 1251699C CN B03126705X A CNB03126705X A CN B03126705XA CN 03126705 A CN03126705 A CN 03126705A CN 1251699 C CN1251699 C CN 1251699C
- Authority
- CN
- China
- Prior art keywords
- treatment
- application
- examples
- prevention
- resisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medical composition for resisting viruses. The medical composition mainly comprises cantharis and milkvetch root, and tangshen, patrinia, glossy privet fruit, selfheal spike and vietnamese sophora root can also be auxiliary added; the medical composition can prevent and treat diseases of infectious atypical pneumonia, influenza and upper respiratory tract infection.
Description
Technical field
The invention belongs to field of medicinal compositions, more particularly relate to a kind of resist virus drugs compositions and application thereof.
Background technology
Severe acute respiratory syndrome is the strong respiratory system disease of a kind of infectiousness.From winter in 2002 so far, in China and popular all over the world, World Health Organization (WHO) thinks that it is that the mutation of a kind of coronavirus hypotype causes, and infectious atypical pneumonia is called SARS (Severe Acute Respiratory Syndrome).So far the specific drug that does not still have anti-coronavirus.And existing medicine all might produce bigger toxicity and side effect.
Summary of the invention
The object of the present invention is to provide a kind of toxic and side effects low resist the virus drugs compositions.
The present invention also aims to provide the application of this pharmaceutical composition in preparation prevention and treatment severe acute respiratory syndrome medicine.
The present invention also aims to provide the application of this pharmaceutical composition in preparation prevention and treatment influenza medicine.
The present invention also aims to provide the application of this pharmaceutical composition in preparation prevention and treatment upper respiratory tract infection disease medicament.
The virus drugs compositions of resisting of the present invention, contain the component of following parts by weight:
Mylabris 0.005-1 part
Radix Astragali 5-89 part
Radix Codonopsis 2-86 part
Herba Patriniae 2-86 part
Fructus Ligustri Lucidi 2-86 part.
The preferable parts by weight of each component are:
Mylabris 0.01-0.5 part
Radix Astragali 10-60 part
Radix Codonopsis 2-86 part
Herba Patriniae 2-86 part
Fructus Ligustri Lucidi 2-86 part.
Preferred plan, wherein the parts by weight of part component are as follows:
Radix Codonopsis 10-60 part
Herba Patriniae 10-60 part
Fructus Ligustri Lucidi 10-60 part.
The virus drugs compositions of resisting of the present invention, can also contain the component of following parts by weight:
Spica Prunellae 2-86 part
Radix Sophorae Tonkinensis 2-60 part.
This is resisted the virus drugs compositions and can be used for the preparation prevention and treat the severe acute respiratory syndrome medicine or be used for preparation prevention and treatment influenza and upper respiratory tract infection disease medicament.
The optimum weight umber of described Spica Prunellae and Radix Sophorae Tonkinensis is as follows:
Spica Prunellae 10-60 part
Radix Sophorae Tonkinensis 5-40 part.
The virus drugs compositions of resisting of the present invention, can also contain the component of following parts by weight again:
Spica Prunellae 2-86 part
Radix Sophorae Tonkinensis 2-60 part
The virus drugs compositions of resisting of the present invention can adopt conventional preparation technology, is prepared into different pharmaceutical dosage forms and uses for the patient, as make oral liquid, capsule, powder etc.
The present invention can effectively prevent and treat infectious atypical pneumonia, influenza, upper respiratory tract infection.The present invention is carried out the toxicity test, and no matter the result is the acute toxicity test of white mice if showing, the rat long term toxicity test still is a Beagle Canis familiaris L. long term toxicity test, all shows the present invention's safety under clinical using dosage.
The specific embodiment
Embodiment 1
Take by weighing Mylabris 500g, Radix Astragali 5000g, Radix Codonopsis 5000g, Herba Patriniae 5000g, Fructus Ligustri Lucidi 5000g, Spica Prunellae 4000g, Radix Sophorae Tonkinensis 3000g, press following explained hereafter oral liquid:
After Mylabris extracted with capacity alkali liquor, filter, filtrate is condensed into A liquid, with the Radix Astragali, Radix Codonopsis, Radix Sophorae Tonkinensis with water extraction after, filter, concentrate, 65% ethanol precipitation reclaims ethanol, centrifugal, the simmer down to relative density is 1.2 solution B liquid; With Herba Patriniae, Fructus Ligustri Lucidi, Spica Prunellae with 50% ethanol extraction after, centrifugal, to be concentrated into relative density be 1.2 solution, leaves standstill, and filters the liquid into C; Merging BC two liquid leave standstill, filter the back and merge with A liquid, fill, and sterilization gets oral liquid, and every milliliter contains raw medicinal herbs 1.63g.
The test of embodiment 2 toxicitys
The oral liquid of getting embodiment 1 gained carries out conventional toxicity test:
The acute toxicity test of white mice draws half lethal dose LD
50Be 236.80g/kg; The rat long term toxicity test shows, oral liquid of the present invention is with 6 middle of the month of 110.0g crude drug/kg.55.0g crude drug/kg and 27.5g crude drug/kg successive administration, (platelet (PLT) counting of 55.0g crude drug/kg, 110.0g crude drug/kg) is than outside the blank group height (p＜0.05, p＜0.01), and the behavior sign of rat, mode of appearance, hematology and blood biochemical are learned and detected, system becomes celestial, organ index, all no abnormal change of histopathologic examination for a good appetite suddenly appearing in a serious disease, high dose group; After recovering in 2 weeks of drug withdrawal, the above-mentioned every detection of each dosage group also no abnormality seen changes, no retardance harmful effect, point out oral liquid of the present invention with 110.0g crude drug/kg, be equivalent to be grown up under 67.5 times of conditions of oral dose every day, general state to rat, the hematology, blood biochemical is learned, system becomes celestial, main organs ponderal index and histopathological examination all have no adverse effects and change, also find no retardance toxicity after the drug withdrawal, can think that the long-term toxicity of using continuously of the present invention is very low, inferring that clinical application safety is better, is 110.0g crude drug/kg to the non-toxic of rat oral administration; Beagle Canis familiaris L. long term toxicity test shows that the present invention is 8.49g/kg to the dosage of the nontoxic reaction of Canis familiaris L..
The prevention and the therapeutic effect of 3 pairs of these examples of severe acute respiratory syndrome of embodiment
Prevention group: medical personnel 43 people that contact closely with patient in the severe acute respiratory syndrome lesion, patient suspected's 75 examples, totally 118 examples.Man 56 people, women 62 people, age 21-65 year.
Treatment group: severe acute respiratory syndrome patient's 91 examples, male 48 examples, women 43 examples, age 19-73 year.
Prevention group and treatment group are taken the oral liquid of embodiment 1: oral, and a 20ml, 3 times on the one, one after each meal, shaking before taking, and 14 days is a course of treatment.
The result: took back 2 months, prevention is organized none example severe acute respiratory syndrome is taken place.Treatment is organized the 91 routine state of an illness and is clearly better, and body temperature took a turn for the better in 3 days, and chest films showed took a turn for the better in 5 days, clinical cure 90 examples, and dead 1 example, dead example also suffer from diabetes, renal failure, coronary heart disease, secondary apoplexy, the death in two days of being in hospital.
Conclusion: medicine of the present invention has tangible prevention and therapeutic effect to severe acute respiratory syndrome.
Embodiment 4 popularity flu and upper respiratory tract infection prevention and treatment of diseases effect
Prevention group: in influenza and upper respiratory tract infection medical personnel 43 people that lesion and patient contact closely that are in hospital, patient suspected's 75 examples, totally 118 examples.Man 56 people, women 62 people, age 21-65 year.
Treatment group: influenza patient's 48 examples, upper respiratory tract infection patient's 43 examples, age 19-73 year.
Prevention group and treatment group are taken the oral liquid of embodiment 1: oral, and a 20ml, 3 times on the one, one after each meal, shaking before taking, and 7 days is a course of treatment.
The result: took back 2 months, prevention is organized none example and is infected.
Treatment is organized the 91 routine state of an illness and is clearly better, clinical cure 90 examples in 7 days; 14 days clinical cure 1 examples, 73 years old age.
Conclusion: medicine popularity flu of the present invention and upper respiratory tract infection disease have tangible prevention and therapeutic effect.
Therapeutic effect
Prevention group: in influenza and upper respiratory tract infection medical personnel 43 people that lesion and patient contact closely that are in hospital, patient suspected's 75 examples, totally 118 examples.Man 56 people, women 62 people, age 21-65 year.
Treatment group: influenza patient's 48 examples, upper respiratory tract infection patient's 43 examples, age 19-73 year.
Prevention group and treatment group are taken the oral liquid of embodiment 1: oral, and a 20ml, 3 times on the one, one after each meal, shaking before taking, and 7 days is a course of treatment.
The result: took back 2 months, prevention is organized none example and is infected.
Treatment is organized the 91 routine state of an illness and is clearly better, clinical cure 90 examples in 7 days; 14 days clinical cure 1 examples, 73 years old age.
Conclusion: medicine popularity flu of the present invention and upper respiratory tract infection disease have tangible prevention and therapeutic effect.
Claims (3)
1, a kind of virus drugs compositions of resisting is characterized in that being made up of the component of following parts by weight:
Mylabris 500
The Radix Astragali 5000
Radix Codonopsis 5000
Herba Patriniae 5000
Fructus Ligustri Lucidi 5000
Spica Prunellae 4000
Radix Sophorae Tonkinensis 3000.
2, the described virus drugs compositions of resisting of claim 1 is in preparation prevention and the application for the treatment of in the severe acute respiratory syndrome medicine.
3, the described virus drugs compositions of resisting of claim 1 is in preparation prevention and the application for the treatment of in influenza and the upper respiratory tract infection disease medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB03126705XA CN1251699C (en) | 2003-05-29 | 2003-05-29 | Antiviral medicine composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB03126705XA CN1251699C (en) | 2003-05-29 | 2003-05-29 | Antiviral medicine composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1456335A CN1456335A (en) | 2003-11-19 |
| CN1251699C true CN1251699C (en) | 2006-04-19 |
Family
ID=29411652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB03126705XA Expired - Lifetime CN1251699C (en) | 2003-05-29 | 2003-05-29 | Antiviral medicine composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1251699C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105902785A (en) * | 2016-06-13 | 2016-08-31 | 上海市静安区卫生事业管理中心 | Traditional Chinese medicine composition for treating slight cold symptom and application thereof |
-
2003
- 2003-05-29 CN CNB03126705XA patent/CN1251699C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1456335A (en) | 2003-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1965853A (en) | Application of gentiopicroside in preparation of antiviral medicament | |
| CN1251699C (en) | Antiviral medicine composition and application thereof | |
| CN1374126A (en) | Medicine for clearing away heat and toxic material and its prepn | |
| CN1259929C (en) | Anti-virus medicine | |
| CN1178119A (en) | Traditional Chinese medicine preparation for treating senile dementia | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN1067258C (en) | Medicinal preparation with extractive from yangtao root and preparing process thereof | |
| CN1432391A (en) | Recipe of Chinese medicine with treating and health care functions | |
| CN1265808C (en) | Combination of medication for anti herpes virus and its application | |
| CN1864713A (en) | Spray for treating influenza and preparation method thereof | |
| CN1883520A (en) | Hypericum perforatum L. phenolic acid and injection thereof preparation method | |
| CN1047944C (en) | Capsule for curing hepatitis | |
| CN1166389C (en) | Inhalation 'Shangfengjing' and its preparing process | |
| CN1051470C (en) | Medicine for curing viral hepatitis | |
| CN1686297A (en) | Cough suppressing panting calming medicine and its preparation method | |
| CN1212150C (en) | Medicine for treating virus hepatitis and its preparation method | |
| CN112891482B (en) | A composition for treating coronavirus infection | |
| CN1470271A (en) | Chinese medicinal compound preparation for treating liver fibrillation disease and its preparation method | |
| CN1634099A (en) | Swerianmarin injectio, its preparation process and application | |
| CN111375036B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof | |
| CN1286460C (en) | Application of l-sophocarpine on preparing medication for curing disease caused by coronavirus | |
| CN1314414C (en) | Chinese traditional medicine for preventing and treating osteoporosis and its preparation process | |
| CN1723907A (en) | Medicinal composition for treating chronic hepatitis B | |
| CN1943658A (en) | A Chinese traditional medicinal composition for treating acute, chronic hepatitis and preparing method | |
| CN1101278A (en) | Chinese medicine for pouldry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060419 |
|
| CX01 | Expiry of patent term |